JMC维卡格雷设计合成

OvercomingClopidogrelResistance:DiscoveryofVicagrelasaHighlyPotentandOrallyBioavailableAntiplateletAgent
JiaqiShan, , BoyuZhang, , YaoqiuZhu,§BoJiao,∥WeiyiZheng,⊥XiaoweiQi,#FushengLv,#andHongbinSun*, ,
YanchunGong, , FangYuan,#
StateKeyLaboratoryofNaturalMedicinesand CenterofDrugDiscovery,CollegeofPharmacy,ChinaPharmaceuticalUniversity,24TongjiaXiang,Nanjing210009,China§
MetabQuestResearchandConsulting,1720OakAvenue,Suite403,Evanston,Illinois60201,UnitedStates∥
DepartmentofPharmacology,SchoolofPharmacy,ShandongUniversity,44WenhuaWestRoad,Jinan250012,China⊥
ConcordPharmatechCo.,Ltd.,9XinglongRoad,Nanjing211800,China#
JiangsuVcarePharmaTechCo.,Ltd.,15WanshouRoad,Nanjing211800,China
*
SupportingInformationClopidogrel(1)(Figure1)isanoralantiplateletagentusedtodiphosphate(ADP)receptorsontheplateletmembrane.Itisapreventbloodclotsincoronaryarterydisease,peripheralprodrugrequiringtwo-stepmetabolicconversionbythevasculardisease,andcerebrovasculardisease.Currently,dualcytochromeP450(CYP)systemtogenerateclopidogrelactivetreatmentwithaspirinandclopidogrelisthecornerstoneofmetabolite(AM,5)viaclopidogrelthiolactone(4a)(Schemeantiplatelettherapyforpatientswithacutecoronarysyndrome1).2However,nonresponsivenessorpoorresponsivenessto(ACS)andpreventionofthromboticeventsafterpercutaneousclopidogreltherapyoccursinupto30%ofCaucasianpatientscoronaryintervention(PCI)withstenting.1Thedrugworksby
(~2%arepoormetabolizers(PMs),~26%areintermediatemetabolizers(IMs)),3especiallyinPMscarryingCYP2C192*loss-of-functionpolymorphism,leadingtolowerlevelsoftheactivemetaboliteofclopidogrel,lessinhibitionofplatelets,anda1-to5-foldhigherriskfordeath,myocardialinfarction,andstrokeincomparisonwithnoncarriers.4,5Thisreferstotheconceptofclopidogrelresistance(CR).In2010,theFDAputablackboxwarningonclopidogreltomakepatientsandhealthcareprofessionalsawarethatCYP2C19PMsareathighriskoftreatmentfailure.Currently,clinicalpracticetoovercomeCRincludes(1)theadjunctiveuseofcilostazol,(2)increasingthedoseofclopidogrel,(3)theuseofnewantiplateletagents,suchasprasugrel(2)andticagrelor(3)(Figure1).6However,theaboveapproachesmayincreasetheriskofmajor7andfatalbleedingsandreducepatientcompliance.Takentogether,therearestillunmetmedicalneedsforthetreatmentofACSanditscomplications,especially
Figure1.StructuresofP2Y12receptorantagonists.

Received:January10,2012Published:March19,

2012
热门文档